Skip to search form
Skip to main content
Semantic Scholar's Logo
Create Free Account
You are currently offline. Some features of the site may not work correctly.
dasatinib 140 MG Oral Tablet [Sprycel]
SPRYCEL 140 MG Oral Tablet
National Institutes of Health
Semantic Scholar uses AI to extract papers important to this topic.
Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.
Corpus ID: 208327523
Dasatinib (Sprycel®, Bristol-Myers Squibb) is an oral potent ATP-competitive multikinase inhibitor active against BCR-ABL and SRC…
Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START…
Corpus ID: 79292956
Dasatinib (SPRYCEL®, formerly BMS-354825) is a novel, oral, multi-targeted kinase inhibitor that induces complete hematologic and…
Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study…
Corpus ID: 208405323
Pts with CML resistant to im have few therapeutic options. A growing body of evidence suggests that treatment outcomes can be…
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Terms of Service
ACCEPT & CONTINUE